Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-16-0343
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Development and Properties of B-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates

English

Impact of Linker-Drug on Ion Exchange Chromatography Separation of Antibody-Drug Conjugates

mAbs
AllergyImmunology
2019English

The Promise of Antibody–Drug Conjugates

New England Journal of Medicine
Medicine
2012English

Site-Specific Antibody Drug Conjugates for Cancer Therapy

mAbs
AllergyImmunology
2013English

Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Antibody-Drug Conjugates in Bladder Cancer

Bladder Cancer
OncologyUrology
2018English

Antibody – Drug Conjugates (ADC) – Drug Discovery Today: Technologies

Drug Discovery Today: Technologies
BiotechnologyDrug DiscoveryMolecular Medicine
2018English

Bispecifics and Antibody–drug Conjugates: A Positive Synergy

Drug Discovery Today: Technologies
BiotechnologyDrug DiscoveryMolecular Medicine
2018English

Studies on Antibody-Anticancer Drug Conjugates

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
1983English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy